CRISPR Therapeutics

53.35
开盘价
52.83
市值
5.21B+
最高价
53.35
最低价
52.36
收盘价
NaN
成交量
346.01K+
市盈率
-8.35
股息率
0.00%

CRISPR Therapeutics简介

CRISPR Treateutics AG是一家基因编辑公司,利用其专有的CRISPR/Cas9平台从事严重疾病基于基因的变革性药物的开发。它的CRISPR/Cas9平台是一种基因编辑技术,允许对基因组DNA进行精确的、定向的改变。该公司提供涵盖广泛疾病领域的治疗方案组合,包括血红蛋白病、肿瘤学、再生医学和罕见疾病。该公司由罗杰·诺瓦克、伊曼纽尔·查彭蒂埃、肖恩·帕特里克·福伊、马修·波特乌斯、丹尼尔·安德森、查德·考恩和克雷格·梅洛于2013年10月31日创立,总部设在瑞士祖格。

如何购买 CRISPR Therapeutics (CRSP)

登录
1分钟开户

1分钟开户

仅需1分钟即可完成账户申请和验证。整个过程完全自助,支持 RockFlow App 和网页端操作。

充值资金

充值资金

账户验证完成后,您可以使用首选的支付方式向账户充值。

购买 CRSP

购买 CRSP

通过 RockFlow App 或网页端搜索 CRSP,输入您想要投资的金额,然后点击确认即可完成交易。

logo

社交媒体

Download

google playapp store

© Rockalpha Limited. All Rights Reserved.

Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.